Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 907-914

  Magenau, John M ^a   Qin, Xuemei ^a,b   Tawara, Isao ^a   Rogers, Clare E ^a   Kitko, Carrie ^a   Schlough, Matthew ^a   Bickley, Daniel ^a   Braun, Thomas M ^c   Jang, Pil Sang ^a,d   Lowler, Kathleen P ^a   Jones, Dawn M ^a   Choi, Sung W ^a   Reddy, Pavan ^a   Mineishi, Shin ^a   Levine, John E ^a   Ferrara, James L M ^a   Paczesny, Sophie ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Uijeongbu St Mary's Hospital   (South Korea)

Author keywords

Acute graft versus host disease; Allogeneic BMT; Biomarker; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MORTALITY; PERIPHERAL LYMPHOCYTE; PROGNOSIS; REGULATORY T LYMPHOCYTE; RELAPSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HUMANS; INFANT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 77953613618     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.026     Document Type: Article

References (31)

1. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
2. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
3. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
4. Stephens L.A., Mottet C., Mason D., Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001, 31:1247-1254.
5. Kronenberg M., Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005, 435:598-604.
6. Yagi H., Nomura T., Nakamura K., et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004, 16:1643-1656.
7. Roncador G., Brown P.J., Maestre L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
8. Wolf D., Wolf A.M., Fong D., et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007, 83:1107-1113.
9. Stanzani M., Martins S.L., Saliba R.M., et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 2004, 103:1140-1146.
10. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
11. Mielke S., Rezvani K., Savani B.N., et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007, 110:1689-1697.
12. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
13. Kawai M., Kitade H., Mathieu C., Waer M., Pirenne J. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005, 79:1073-1077.
14. Coenen J.J., Koenen H.J., van Rijssen E., et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007, 39:537-545.
15. Noel G., Bruniquel D., Birebent B., et al. Patients suffering from acute graft-versus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells. Clin Immunol 2008, 129:241-248.
16. Sanchez J., Casano J., Alvarez M.A., et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004, 126:697-703.
17. Bacchetta R., Gambineri E., Roncarolo M.G. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007, 120:227-235.
18. Miyara M., Yoshioka Y., Kitoh A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
19. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990.
20. Pzrepiorka D., Weisdorf D., Martin P., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
21. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
22. Miyara M., Amoura Z., Parizot C., et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006, 203:359-370.
23. Liu W., Putnam A.L., Xu-Yu Z., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
24. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
25. Battaglia M., Roncarolo M.G. The fate of human Treg cells. Immunity 2009, 30:763-765.
26. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
27. Schneider M., Munder M., Karakhanova S., Ho A.D., Goerner M. The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation. Clin Lab Haematol 2006, 28:382-390.
28. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
29. Zeiser R., Leveson-Gower D.B., Zambricki E.A., et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-462.
30. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006, 177:8338-8347.
31. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008, 112:1515-1521.